Your browser doesn't support javascript.
loading
Application of cinnarizine in migraine prevention: A systematic review and meta-analysis.
Shafie'ei, Mohammad; Kouhanjani, Mohsen Farjoud; Akbari, Zahra; Sarvipour, Nastaran; Shekouh, Dorsa; Gholampour, Mohammadhasan; Ardestani, Pooneh Memar; Nemati, Hamid.
Afiliação
  • Shafie'ei M; Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
  • Kouhanjani MF; Professor Alborzi Clinical Microbiology Research Center, Shiraz, Iran.
  • Akbari Z; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Sarvipour N; Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
  • Shekouh D; Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
  • Gholampour M; Student Research Committee, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Ardestani PM; Shiraz University of Medical Sciences, Shiraz, Iran.
  • Nemati H; Einstein Healthcare Network, Philadelphia, Pennsylvania, USA.
Pain Pract ; 22(8): 733-745, 2022 11.
Article em En | MEDLINE | ID: mdl-36148684
ABSTRACT

OBJECTIVE:

To investigate and analyze the available data on the prophylactic effectiveness of cinnarizine in migraine disorder.

BACKGROUND:

Cinnarizine has demonstrated encouraging potential in preventing the attacks of migraine. Therefore, we opted to evaluate whether its sole administration leads to positive outcomes.

METHODS:

The PubMed, Scopus, Web of Science, and Embase databases were searched for English-only original interventional studies published until April 2022, then screened for relevancy and eligibility. The resulting data from the included studies, including the primary (ie, headache episode frequency, intensity, duration, monthly timing, and analgesic intake frequency) and secondary (ie, reported adverse events, quality of life, and activities of daily living) outcome changes compared to placebo and active controls (e.g., sodium valproate and propranolol) were then recorded by two independent assessors. Ultimately, these data were synthesized qualitatively and quantitatively (achieved by determining the mean difference via the random-effects model).

RESULTS:

A total of 10 studies comprising seven randomized controlled trials and three quasi-experimental studies were included. Compared to placebo, cinnarizine demonstrated significant improvements in migraine episode frequency (Mean difference = -3.10; Confidence interval = [-3.33, -2.88]; p-value < 0.001; I2  < 0.001%), and intensity (Mean difference = -1.54; Confidence interval = [-2.08, -0.99]; p-value < 0.001; I2  < 37.97%). Moreover, cinnarizine led to similar or better results when compared to active controls, including sodium valproate, topiramate, and propranolol.

CONCLUSIONS:

Cinnarizine can be considered a safe and effective medication for migraine prophylaxis. However, the relatively small sample size made reaching a definite conclusion impossible. Therefore, a higher number of randomized controlled trials are recommended to be taken place to clarify the situation further.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cinarizina / Transtornos de Enxaqueca Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Humans Idioma: En Revista: Pain Pract Assunto da revista: NEUROLOGIA / PSICOFISIOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Irã

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cinarizina / Transtornos de Enxaqueca Tipo de estudo: Clinical_trials / Systematic_reviews Limite: Humans Idioma: En Revista: Pain Pract Assunto da revista: NEUROLOGIA / PSICOFISIOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Irã